1620 Investment Advisors, Inc. Pacira Bio Sciences, Inc. Transaction History
1620 Investment Advisors, Inc.
- $126 Million
- Q4 2024
A detailed history of 1620 Investment Advisors, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 992 shares of PCRX stock, worth $24,770. This represents 0.01% of its overall portfolio holdings.
Number of Shares
992
Previous 1,027
3.41%
Holding current value
$24,770
Previous $15,000
20.0%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding PCRX
# of Institutions
259Shares Held
49.5MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$200 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$131 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$81.5 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$56.4 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$49.8 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.14B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...